Boehringer's Hernexeos secures speedy first-line expansion in FDA's 2nd national priority nod

26th February 2026 Uncategorised 0

Less than six months after debuting as the first drug that can target a rare tumor type in patients with non-small cell lung cancer, Boehringer Ingelheim’s Hernexeos has quickly widened its reach into the first-line setting with the help of an FDA Commissioner’s National Priority Voucher (CNPV).

More: Boehringer's Hernexeos secures speedy first-line expansion in FDA's 2nd national priority nod
Source: fierce